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Abstract 
Tumor metastases, the most fearsome aspect of cancer, are generally resistant to conventional therapies. Angio-
genesis is a crucial aspect of tumor growth and metastatic dissemination. Antiangiogenic therapy, therefore, 
holds potential as an attractive strategy for inhibiting metastasis development. Human 16K PRL (16K hPRL), a 
potent inhibitor of angiogenesis, has been demonstrated to prevent tumor growth in two xenograft mouse 
models, but whether it also affects tumor metastasis is unknown. In this study we will investigate the ability of 
16K hPRL to prevent the establishment of metastasis. We demonstrate that 16K hPRL administered via 
adenovirus-mediated gene transfer, inhibits tumor growth by 86% in a subcutaneous (SC) B16-F10 mouse 
melanoma model. Computer-assisted image analysis shows that 16K hPRL treatment results in a reduction of 
tumor-vessel length and width, leading to a 57% reduction of average vessel size. In a pre-established tumor 
model, moreover, 16K hPRL can significantly delay tumor development. Finally, for the first time, we provide 
evidence that 16K hPRL considerably reduces the establishment of B16-F10 metastasis in an experimental lung 
metastasis model. Both the number and size of metastases are reduced by 50% in 16K hPRL-treated mice. These 
results highlight a potential role for 16K hPRL in anticancer therapy for both primary tumors and metastases. 
 
INTRODUCTION 
Tumor metastasis is the most fearsome aspect of cancer, responsible for most cancer patient morbidity and 
mortality. Metastases are resistant to conventional therapies because of their biological heterogeneity and the 
influence of the organ environment. Therapeutic strategies for preventing metastasis have the potential to reduce 
cancer mortality.1,2
Angiogenesis, i.e., the formation of new blood vessels from pre-existing ones, is a key event in tumor growth.3 
This process is also crucial for tumor metastasis, as blood vessels provide tumor cells with an efficient route for 
leaving the primary site via the bloodstream.4 Angiogenesis is a complex process regulated by both activators 
and inhibitors of endothelial cell apoptosis, proliferation, migration, and organization. Many proteins (including 
their growth factors, their receptors, extracellular matrix proteins, and matrix metalloproteinases), are involved in 
this process. Great efforts have been made to discover new antiangiogenic factors, and antiangiogenic therapy is 
now considered an important approach to treating cancer.3,5
16K PRL, the 16-kd N-terminal fragment of prolactin, is among the most potent of the known negative 
regulators of angiogenesis. We have previously shown that 16K PRL is antiangiogenic in both in vitro and in 
vivo models.6-11 Very recently, human 16K PRL (16K hPRL) was shown to mediate postpartum 
cardiomyopathy.12 16K hPRL, produced by human HCT116 colon cancer cells, markedly reduces their ability to 
form subcutaneous (SC) tumors in Rag1-/- mice.13 Furthermore, Kim and collaborators have demonstrated that 
adenovirus-mediated 16K hPRL expression by prostate cancer cells leads to tumor growth inhibition.14 However, 
it is unknown whether 16K PRL has an impact on metastasis. More recently, we have shown that 16K hPRL 
inhibits retinal neovascularization in a mouse model, in a non-cancer angiogenesis-related disease: oxygen-
induced retinopathy.15 This ability to prevent angiogenesis in both tumor and retinopathy mouse models has 
raised great interest, notably in the potential use of 16K hPRL as an anticancer agent. 
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The usefulness of recombinant antiangiogenic proteins in the clinical treatment of cancer appears limited, due to 
the short half-life of the potentially therapeutic proteins (requiring repeated injections within a short period of 
time), the high therapeutic dose required, toxicity due to production in microorganisms, and high production 
costs. Gene therapy with angiogenesis inhibitors seems more promising, as it does not require a high dose of 
DNA molecules for injection and provides a sustained level of therapeutic molecules.16 Antiangiogenic gene 
therapy with viral vectors has proved effective in the treatment of cancer in animal models, notably in the case of 
vectors transferring an angiostatin, endostatin, PF-4, or TIMP-2 gene.16-18
In the present study, we have used well-characterized mouse models of primary tumor development and 
metastasis establishment (based on the use of B16-F10 melanoma cells) to investigate the effect of 16K hPRL on 
these processes. We provide evidence that 16K hPRL, administered by adenovirus-mediated gene transfer, can 
alter vascular morphology in primary tumors and reduce their growth. We also show, for the first time, that 16K 
hPRL exerts a striking inhibitory effect on metastasis development. 
RESULTS 
The 16K-Ad adenovirus vector drives expression of 16K hPRL 
To analyze the effect of 16K hPRL on tumor growth and metastasis, we used 16K-Ad, an adenovirus vector that 
mediates 16K hPRL gene transfer. Western blot analysis of 16K hPRL produced in a medium conditioned by 
COS cells infected with 16K-Ad, showed high levels of 16K hPRL isoforms. Three bands for 16K hPRL were 
observed on the Western blot, the major band migrating slightly more slowly than the recombinant 16K hPRL 
produced in Escherichia coli (Figure 1). As previously shown in ref. 15, we suggest that 16K hPRL was mainly 
produced in a glycosylated form. 
 
Figure 1: 16K-Ad adenovirus vector can drive expression of human 16K PRL (16K hPRL). Thirty microliters of 
conditioned medium from a culture of COS cells infected with 16K-Ad [multiplicity of infection (MOI): 200 plaque forming units (pfu)/cell] 
or Null-Ad (MOI: 200pfu/cell) was subjected to Western blot analysis with an anti-16K hPRL antiserum. Thirty nanograms of recombinant 
16K hPRL produced in Escherichia coli was loaded as a control (16K). 
 
 
Figure 2: Human 16K PRL (16K hPRL), 16K-Ad, and Null-Ad do not affect B16-F10 cell viability. B16-F10 cell 
viability was unaffected when the cells were treated for 72 hours with recombinant 16K hPRL produced in Escherichia coli (50 nmol/l) or 
infected with either 16K-Ad [multiplicity of infection (MOI): 100, 200, and 400 plaque forming units (pfu)/cell] or Null-Ad (MOI: 100, 200, 
and 400pfu/cell). Un, untreated cells; Cam, camptothecin-treated cells, a positive control. Viability was evaluated by means of the calcein 
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16K hPRL and the 16K-Ad adenovirus vector have no effect on B16-F10 viability 
In order to determine whether recombinant 16K hPRL or adenovirus vector administration has a direct effect on 
B16-F10 tumor cells, cell viability was evaluated after incubating B16-F10 cells with 50nmol/l recombinant 16K 
hPRL produced in E. coli, or infecting them with 16K-Ad or Null-Ad at an increasing multiplicity of infection 
[100, 200, and 400 plaque forming units (pfu)/cell]. Results revealed no effect of recombinant 16K hPRL, 16K-
Ad, or Null-Ad, whilst camptothecin, an inhibitor of topoi-somerase I used as a positive control, caused cell 
fluorescence to decrease dramatically (Figure 2). 
Inhibition of tumor growth and modification of vascular morphology by 16K hPRL 
To determine whether 16K hPRL affects B16-F10 melanoma tumor growth, we injected B16-F10 mouse 
melanoma cells SC into C57BL/6J mice and inoculated the mice with either 5 × 108pfu of 16K-Ad or 5 × 108pfu 
of Null-Ad control. Treatment with the adenovirus vector was repeated five times during the experiment.                      
We monitored the effect of 16K hPRL on the tumor growth rate in two independent experiments. In both 
experiments, 16K hPRL-treated mice showed reduced tumor incidence and tumor growth (Figure 3a-c). At the 
end of the first experiment, the tumor incidence was 50% (5 of 10 tumors) in the 16K-Ad-treated mice and 100% 
(8 out of 8 tumors) in the control group. In a second experiment, the tumor incidence was 45% (5 of 11 tumors) 
in the 16K-Ad-treated mice and 89% (8 of 9 tumors) in the Null-Ad-treated mice (Figure 3a). On the day of kill, 
the mean tumor volume was 86% lower in the 16K hPRL group than in the control group (Figure 3b). 
Considering the previously described ability of 16K hPRL to inhibit tumor angiogenesis in vivo,13,14 we 
evaluated the ability of 16K hPRL to affect tumor vascularization. Immunostaining for CD31 revealed 
interesting differences, in terms of morphology and size, between tumor vessels in the two groups: the blood 
vessels in 16K-Ad-treated tumors appeared smaller and collapsed (Figure 4a). Computer-assisted image analysis 
(Figure 4b, see Materials and Methods) was then used to quantify vessel density, vessel area density, and vessel 
size distribution. Surprisingly, the average vessel density (number of CD31-positive vessels/mm2 tumor area) in 
Null-Ad-treated mice was 40% lower than in 16K-Ad-treated mice, whilst the percentage area covered by 
vessels was similar (Figure 4c and d). The difference between these two results can be explained as revealed by 
vessel size distribution histograms (Figure 4e): larger vessels disappear in the 16K-Ad-treated group, leading to a 
57% reduction of average vessel size (Figure 4e and f). 
 
Figure 3: Reduction of tumor growth by human 16K PRL. C57BL/6J mice were inoculated subcutaneously with 
105 B16-F10 cells and, 1 day later, with 5 × 108 plaque forming units (pfu) of 16K-Ad or Null-Ad. Adenovirus 
vector injection was done five times. Two different experiments were performed. (a) Tumor incidence, defined as the percentage of mice 
bearing a tumor exceeding 100mm3 on the day of killing. (b) Mean tumor volume ± SEM in mice implanted with 105 B16-F10 cells and 
treated every 2 days with 5 × 108 pfu 16K-Ad (n = 10) or control Null-Ad (n = 8) adenovirus vector. A significant difference with respect to 
the control (Null-Ad) is denoted by *P < 0.05. Two different experiments were performed, (c) Tumor volumes in mice at the end of the 
assay. Horizontal lines indicate the median tumor volume. 
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Figure 4: Reduction of tumor vessel area by human 16K PRL. (a) Representative photographs of tumor sections 
from 16K-Ad- and Null-Ad-inoculated mice, stained with anti-CD31 to reveal blood vessels (red) (x100 
magnification). Bar: 100 µm. (b) Image processing as described under Materials and Methods. (A) Original red-green-blue color image. 
(B) Extraction of the red component. (C) Binary image of vessels (D) Labeled vessels. (c) The average vessel density + SEM was determined 
on CD31 -positive vessels in x100 power fields of each section as described under Materials and Methods. (d) Total vessel area + SEM was 
determined on CD31 -positive vessels in x100 power fields of each section as described under Materials and Methods. (e) The size 
distribution + SEM was determined on CD31 -positive vessels in x100 power fields of each section as described under Materials and 
Methods. (f) The average vessel size + SEM was determined on CD31-positive vessels in x100 power fields of each section as described 
under Materials and Methods. A significant difference with respect to the control (Null-Ad) is denoted by *, P < 0.05. 
 
 
Figure 5: Human 16K PRL delays development of established tumors. C57BL/6J mice were inoculated 
subcutaneously with 105 B16-F10 cells. When their tumor size reached ~50mm3, they were injected with 5 × 108 plaque forming 
units of 16K-Ad (n = 6) or control Null-Ad (n = 8) adenovirus vector. Mean tumor volume + SEM. A significant difference with respect to 
the control (Null-Ad) is denoted by *, P < 0.05. 
 
These results show that the antiangiogenic factor 16K hPRL can strongly reduce the development of B16-F10 
melanoma by altering tumoral vasculature. 
To examine the effect of 16K hPRL on the growth of established tumors, we injected recombinant adenovirus 
into melanoma tumors in C57BL/6J mice. The tumors were established in mice by injection of B16-F10 into the 
flank, and the recombinant adenoviruses were injected later when the tumors reached ~50 mm3. SC injections of 
adenovirus vector were performed, 2 days apart. Significant inhibition of tumor growth was observed in 16K-
Ad-treated mice: it took 2 days longer for tumors to reach the target size (~1.5 cm3) (Figure 5) in these mice than 
in control mice. 
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Inhibition of experimental lung metastasis by 16K hPRL 
Because metastasis is the leading cause of death in cancer patients, we then used an experimental lung metastasis 
assay to see whether 16K hPRL can affect metastatic outgrowth. The assay involved injecting B16-F10 cells into 
the tail vein of mice and observing the difference in metastasis establishment in the lung, between 16K-Ad-
treated animals and untreated animals. 
Western blot analysis revealed 16K hPRL in the sera of 16K-Ad-treated mice 7 and even 13 days after a single 
intravenous (IV) injection of adenovirus. 16K hPRL was not detected in the sera of Null-Ad-treated mice (Figure 
6a). As previously observed in vitro, the predominant 16K hPRL isoform present in mouse serum migrated more 
slowly than recombinant 16K hPRL. Macroscopic observation of the lungs of mice treated with 109 pfu of 16K-
Ad revealed only a few black tumor nodules, small in size. The lungs of control mice, on the other hand, showed 
multiple large tumor nodules that replaced the lung parenchyma (Figure 6b). Macroscopic quantification of 
tumor nodules on the lung surface revealed 50-60% fewer metastases in the 16K-Ad group than in the control 
group (Figure 6c). To further characterize the anti-metastatic effects of 16K hPRL, a histological examination of 
hematoxylin/eosin-stained lung tissues was done (Figure 6d). The extent of lung metastasis was assessed in 
terms of the number and size of metastases. Lungs of 16K-Ad-treated animals showed significantly fewer (50% 
fewer) metastases than those of control animals (Figure 6e). We graded the observed metastases according to 
three size levels: small (<200µm in diameter), medium (200µm to 1mm in diameter), and large (>1mm in 
diameter). The number of medium- and large-sized metastases was lower in the 16K-Ad-treated animals (Figure 
6e). 
We then repeated this experiment, repeating the injection and extending the period over which the effect of 16K 
hPRL was monitored. We first injected B6-F10 into the tail vein of each mouse. The mice then received two 
adenovirus vector injections, one after 2 days and one a week later. Thirteen days after the second 16K-Ad 
injection was made, we observed the striking effect that 16K hPRL had in preventing the establishment of 
metastases in the lung. The lungs of 16K-Ad-treated animals showed almost no tumor nodules, in contrast to 
control lungs. Yet 5 days later, the lungs of both groups looked similar, with tumor nodules covering the lung 
parenchyma (Figure 7a). Anti-CD31 was then used to immunostain blood vessels in sections of healthy lung and 
liver tissue from both 16K-Ad-treated, and untreated, mice. Treatment was found to have no significant effect on 
vascular morphology in either tissue (Figure 7b). 
Taken together, these results show that 16K hPRL can inhibit tumor growth and metastasis establishment from 
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Figure 6: Inhibition of experimental lung metastasis by human 16K PRL (16K hPRL). C57BL/6J mice were inoculated 
intravenously with 105 B16-F10 cells and, 2 days later, with 109 plaque forming units (pfu) of 16K-Ad or Null-Ad. Two different 
experiments were performed. (a) Western blot detection of 16K hPRL in 30µl immunoprecipitates from two mice inoculated with 16K-Ad 
(1-4) or Null-Ad (5-8). Odd number, immuno-precipitate from serum collected 7 days after adenoviral vector injection. Even number, 
immunoprecipitate from serum collected 13 days after adenoviral vector injection. (b) Representative photographs of lungs from mice treated 
with 16K-Ad or Null-Ad. (c) Mean number (± SEM) of metastatic foci on the surface of lungs from mice treated with 16K-Ad (n = 9) or 
Null-Ad (n = 8). (d) Representative lung sections stained with hematoxylin/eosin (x100 magnification). Bar: 100µm. (e) The number and size 
of internal pulmonary metastases were quantified. The histogram on the left represents the mean number of total metastases. The histogram 
on the right represents the distribution of metastases as a function of their diameter. Results are means ± SEM for eight mice treated with 
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Figure 7: Metastasis establishment delayed by human 16K PRL. 
(a)  Representative photographs of lungs collected on days 22 and 27, from mice treated with 16K-Ad or Null-Ad. C57BL/6J mice were 
inoculated intravenously on day 0 with 105 B16-F10 cells and, 2 days later, with 109 plaque forming units (pfu) of 16K-Ad or Null-Ad. One 
week later, the mice were again inoculated with 109pfu 16K-Ad or Null-Ad. 
(b)  Representative photographs of lung and liver sections from 16K-Ad- and Null-Ad inoculated mice (organs collected on day 22). The 




In the present study, we have evaluated the effects of 16K hPRL on two angiogenesis-dependent pathological 
phenomena: tumor growth and metastasis. B16-F10 murine melanoma cells were selected for their well-known 
high aggressiveness and their high lung metastatic potential. 
We first showed that 16K hPRL gene therapy can effectively inhibit melanoma growth by 86% in a SC mouse 
model with tumor development. In a second experiment we showed, using a pre-established tumor model, that 
16K hPRL can significantly delay tumor development, although the effect is weaker than observed in the 
previous model. The observed effect appears to be indirect, since neither recombinant 16K hPRL produced in        
E. coli nor the 16K-Ad adenovirus vector had any toxic effect on cultured B16-F10 cells. Prior to this work, only 
two reports have described the antitumor action of 16K hPRL: one by Bentzien et al., who observed inhibition of 
tumor growth in Rag1-/- mice treated with human HCT116 colon cancer cells expressing 16K hPRL,13 and one 
by Kim et al., reporting tumor growth inhibition in nu/nu mice receiving implants of PC-3 or DU145 human 
prostate cancer cells expressing 16K hPRL.14 Both reports demonstrate a correlation between inhibition of in 
vivo tumor growth by 16K hPRL and decreased microvessel density in the tumor. These observations suggest 
that reduced blood vessel formation may contribute to decreased tumor growth after 16K PRL treatment. In our 
study, vessel density was not reduced, but for the first time, we provide evidence that 16K hPRL affects the 
morphology of tumor blood vessels. This idea has emerged from CD31 immunostaining and computerized 
quantification that reveal that blood vessels became smaller and somewhat collapsed after 16K hPRL treatment. 
Computer-assisted image analysis revealed a 57% decrease in average vessel size in Ad-16K-treated tumors as 
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compared to those treated by Null-Ad. Thrombos-pondin-2, another angiogenesis inhibitor, and cannabinoids19,20 
are reported to similarly affect tumor-vessel morphology. In ref 19, the average vessel size was reduced in 
thrombospondin-2-overexpressing hA431 squamous tumors as compared to control tumors. In ref. 20, 
cannabinoids known to induce tumor regression in rodents were also shown to inhibit tumor angiogenesis. 
Although cannabinoid administration did not affect the microvascular count in gliomas, a notable effect was 
observed on blood vessel morphology: the vessels were characterized by very small and narrow capillaries. 
How does 16K hPRL affect tumor vessel morphology? 16K hPRL might affect vascular tone. It is known to 
inhibit endothelial nitric oxide synthase activation by blocking intracellular Ca2+ mobilization, and this action 
results in inhibition of both angiogenesis and vasorelaxation.21
Tumor metastasis is the primary cause of mortality in cancer patients. Angiogenesis is important not only for 
primary tumor growth, but also for metastatic spread and growth of metastatic foci at distant sites. A high degree 
of tumor vascularization increases the likelihood that tumor cells will enter the bloodstream and metastasize.22 
Thus, inhibition of angiogenesis is an attractive approach to limiting metastasis. Numerous anti-angiogenic 
factors, including angiostatin and endostatin, have been shown to inhibit both tumor development and metastatic 
spread and growth.23,24 To our knowledge, no previous report has described any inhibitory effect of 16K hPRL 
on metastasis. The metastatic process generally proceeds in steps, starting from the growth and vascularization of 
the primary tumor, escape of cells from the primary tumor into the bloodstream or lymph system (intravasation), 
transport of cells to distant organs, escape from the blood or lymph stream into the new tissue (extravasation), to 
growth and vascularization of the new metastatic tumor. The metastasis assay used here is designed to model the 
latter half of the metastatic process.1 The results clearly show that 16K hPRL can exert a striking effect on lung 
metastasis development. Macroscopic and histological examinations revealed fewer and smaller metastases in 
the lungs of animals treated with the 16K-Ad adenovirus vector. Grading the observed metastases according to 
three sizes or levels further suggested that metastases are less invasive in 16K-Ad-treated mice than in control 
mice; this is because significantly fewer medium-sized (200 µm to 1 mm in diameter) and large metastases            
(>1 mm in diameter) were observed in the former. This observation suggests that 16K affects both tumor cell 
implantation at a secondary site as well as tumor growth in this new environment. In accordance with this, a 
previous study has also shown that treatment with the angiogenesis inhibitor thienopyridine SR 25989 reduces 
the size and number of lung metastases in a similar metastasis model.25 Our results show that it should be 
possible to limit the metastatic process to the development of small metastases that might mostly have only 
minimal clinical consequences for patients. 
The inhibition of metastasis development in the lung correlates with the presence of 16K hPRL in serum samples 
from 16K-Ad-treated mice. The major 16K hPRL form detected in mouse serum appears to migrate more slowly 
than the 16K hPRL expressed in E. coli. This is in agreement with previous results suggesting that biologically 
active 16K hPRL exists in multiple forms arising most likely through post-translational modification.14,15               
The major 16K hPRL isoform detected is probably the glycosylated form previously shown in a study by Pan.15 
The relevance of such post-translational modifications is unknown. 
In the metastasis model where the mice received two injections of 16K-Ad adenovirus vector, the efficacy of 
16K hPRL administration was strong at first but then diminished, as attested by rapid development of tumor 
nodules in the lung. By day 27, treated and untreated lungs appeared equally affected, and this correlated with an 
undetectable serum level of 16K hPRL (data not shown), probably due to rapid clearance of the adenovirus 
vector by the murine organism. This result demonstrates the need to improve delivery of the vector to the tumor 
vasculature. 
The major obstacle to achieving delivery of IV-administered adenoviral vectors to tumor-vasculature, endothelial 
cells and tumor cells is the nonspecific uptake of adenoviral vectors in the liver and other organs. To circumvent 
this problem, new adenovirus vectors targeting the tumor vasculature have been engineered. For example, Niu 
and collaborators have shown that introducing the RGD peptide into the adenoviral fiber protein increases 
binding of the adenoviral vector to tumor-vasculature endothelial cells and tumor cells.26 Liu and collaborators, 
moreover, have shown that IV pre-administration of 6% hetastarch before adenoviral vector administration 
increases delivery of the adenoviral vector to tumor cells and their vasculature, reduces uptake by normal tissue, 
and reduces vector-mediated toxicity toward the liver.27
In conclusion, this study demonstrates that 16K hPRL gene therapy can inhibit tumor growth. It is the first study 
to show inhibition of metastasis establishment by 16K hPRL treatment. These results suggest that the 
antiangiogenic factor 16K hPRL may have high therapeutic potential in cancer treatment. Further studies will be 
undertaken to determine whether 16K hPRL might also act on lymphangiogenesis, the formation of new lymph 
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vessels, to inhibit tumor and metastatic growth. 
MATERIALS AND METHODS 
Production of recombinant proteins 
Recombinant 16K hPRL was produced in E. coli as previously described.10 The 16K hPRL coding sequence was 
obtained by site-directed mutagenesis performed on the complementary DNA encoding hPRL (minus the 
corresponding signal peptide) inserted into the pT7L expression vector.28 An ATG was genetically engineered 5' 
from the first codon, Cys 58 (TGC) was mutated to serine (TCC) to avoid incorrect disulfite bonds, and Glu 140 
(GAA) was mutated to TAA to generate a premature stop codon. Briefly, after induction of protein expression by 
treatment with isopropyl-β-D thiogalactopyranoside, the cells (E. coli BL21 DE3) were disrupted. The inclusion 
bodies were solubilized in 20nmol/l ethanolamine-HCl (pH 9) containing 8mol/l deionized urea and 1% β-
mercaptoethanol, heated at 55 °C for 10 minutes, and incubated overnight at room temperature (RT). Denatured 
proteins were then purified as described in.10
The purity of the recombinant protein exceeded 95% (as estimated by Coomassie blue staining), and the 
endotoxin level was 0.0005 ng/ng recombinant protein, as quantified with the rapid endo test of the European 
Endotoxin Testing Service (BioWhittaker, Verviers, Belgium). 
Adenovirus vectors 
 16K-Ad is a defective recombinant E1-E3-deleted adenovirus vector encoding a secreted peptide consisting of 
the first 139 amino acids of PRL. This adenovirus vector was constructed as described in ref. 15, using the 
Adeno-X expression system (BD Biosciences, Erembodegem, Belgium). Briefly, the 16K hPRL complementary 
DNA was cloned into a pShuttle vector in an expression cassette that was then inserted into the Adeno-X viral 
DNA. Recombinant adenoviruses were constructed and amplified in HEK 293 cells. The BD Adeno-X Virus 
Purification kit (BD Biosciences, Erembodegem, Belgium) and the Adeno-X Rapid Titer kit (BD Biosciences, 
Erembodegem, Belgium) were used to perform purification and titration, respectively, of the recombinant 
adenoviruses (by following the manufacturer's instructions). Null-Ad is a control adenovirus carrying an empty 
expression cassette. 
Mice 
Adult female C57BL/6J mice (6-8 weeks of age) purchased from the Central Animal Facility of Central 
Hospitalier Universitaire de Liège (Liège, Belgium) were used to assess tumor growth and experimental lung 
metastasis. The animal experiment protocols observed were all approved by the Institutional Ethics Committee 
of the University of Liège. 
Cell cultures 
COS cells were cultured in a low-glucose Dulbecco's modified Eagle's medium supplemented with 10% fetal 
calf serum and 4 mmol/l glutamine, 100U/ml penicillin, and 100µg/ml streptomycin at 37°C in a 5% CO2 humid 
atmosphere. B16-F10 mouse melanoma cells were obtained from the American Type Culture Collection (CRL-
6475, Rockville, MD) and cultured in a high-glucose Dulbecco's modified Eagle's medium supplemented with 
10% fetal calf serum and 4mmol/l glutamine, 100U/ml penicillin, 100µg/ml streptomycin at 37°C in a 5% CO2 
humid atmosphere. All culture reagents were purchased from Invitrogen/Life Technologies (Paisley, Scotland). 
Viability assay 
B16-F10 cells were plated at a density of 2.5 × 104cells/well (in 24-well plates) in 0.5 ml growth medium. Cells 
were infected with an adenovirus vector at an increasing multiplicity of infection or treated with 10µmol/l 
campthotecin (Sigma-Aldrich, Bornem, Belgium) for 72 hours. After washing with phosphate-buffered saline 
(PBS) and incubation with 1 µmol/l calcein-AM (Calbiochem, San Diego, CA) for 30 minutes at RT, cell 
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In vivo tumorigenicity 
Subconfluent B16-F10 cells were trypsinized, washed, and resuspended in PBS. In the first experiment, cell 
suspension (105 cells in 50 µl) was injected SC into the right flank of C57BL/6J mice. Groups of 12 mice were 
used and randomly divided. One day later, either a 5 × 108pfu Null-Ad or 5 × 108pfu 16K-Ad adenovirus vector, 
was inoculated SC into the peritumoral region. This injection was repeated every 3 days. Sixteen days after cell 
injection, the mice were killed and their tumors harvested. Tumor growth was assessed by measuring the length 
and width of each tumor, every 1 or 2 days, and calculating its volume by means of the formula: length × width2 
× 0.5 (ref. 29). Results are expressed as the mean tumor volume for each experimental group. Tumor incidence is 
defined as the percentage of mice bearing a tumor larger than 100 mm3 on the day of killing. 
In a second experiment, when the tumors reached the average size of ~50 mm3, the mice were randomized and 
treated with either 5 × 108pfu 16K-Ad or 5 × 108pfu Null-Ad. Adenovirus administration was repeated every 2 
days. 
In vivo experimental lung metastasis assay 
In order to mimic the metastatic process, 105 B16-F10 cells in 50µl PBS were injected IV into the lateral tail vein 
of C57BL/6J mice. Groups of 12 mice were used and randomly divided. Two days later, 109pfu Null-Ad or 16K-
Ad adenovirus vector was injected IV into the lateral tail vein. Blood was collected 7 and 13 days after 
adenovirus vector injection. The mice were killed 15 days after tumor cell injection and their lungs harvested. 
Metastatic colonies were counted macroscopically on the lung surface and microscopically on lung sections. 
In a second experiment, 105 B16-F10 cells in 50µl PBS were injected IV into the lateral tail vein of C57BL/6J 
mice. They were then treated twice with adenovirus vector, once 2 days after B16-F10 injection and once 1 week 
later. Some of the mice (n = 7/group) were killed 22 days after tumor cell injection and the remaining mice (n = 
4/group) were killed 5 days later. 
Immunoprecipitation 
Fifty microliters of serum collected from the lung metastasis experiment was added to 450µl PBS containing 
protease inhibitors (Complete Mini Protease Inhibitor Cocktail) (Roche, Mannheim, Germany). The different 
sera were then incubated with 50µl protein A agarose (Roche, Mannheim, Germany) for 1 hour at 4°C under 
rotation. The solutions were centrifuged for 20 seconds at 6,000 rpm and 4 °C, then incubated on ice for 5 
minutes. Ten microliters of rabbit polyclonal anti-16K hPRL antiserum (SB30) was added to each supernatant 
and the mix was incubated for 3 hours at 4°C under rotation. Fifty microliters of protein A agarose was added to 
the mix and incubated overnight at 4 °C under rotation. After centrifugation for 20 seconds at 6,000 rpm and 
incubation on ice for 5 minutes, the supernatants were discarded and the pellets (containing the beads) were 
washed three times with PBS. After a new centrifugation, the beads were resuspended in 30 µl 1× β-
mercaptoethanol loading buffer and boiled at 100 °C for 5 minutes, then left on ice for 5 minutes. The beads 
were centrifuged for 5 minutes at 4 °C; then the supernatants were subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (12% acrylamide) for Western blot analysis. 
Western blot analysis 
Proteins in 30µl immunoprecipitate or 30µl medium conditioned with COS cells infected at increasing an 
multiplicity of infection with 16K-Ad or Null-Ad were resolved by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis and transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, MA). Membranes 
were saturated for 1 hour in Tris-buffered saline-8% dry milk, followed by incubation for 1 hour with a 1/500 
dilution of anti-16K hPRL antibody (SB30 for immunoprecipitates; A602 for conditioned media) and for 1 hour 
with a 1/5,000 dilution of peroxidase-conjugated goat antirabbit antibody (Gamma; BioWhittaker, Verviers, 
Belgium). 16K hPRL detection was carried out by chemiluminescence using the ECL Plus kit (Amersham 
Biosciences, Arlington Heights, IL). 
Histology and immunohistochemistry 
Tumors and lungs were either embedded in Tissue-Tek (Sakura Finetek, Zoeterwoude, The Netherlands) and 
frozen at -70°C or fixed in 4% paraformaldehyde for 3-4 hours, dehydrated, and embedded in paraffin 
(Labonord, Templemars, France). The tissues were then sectioned (6µm thick). To study overall tissue 
morphology, slides of paraffin sections were soaked in Xylol (Sigma-Aldrich, Steinheim, Germany) to 
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deparaffinize them, then rehydrated in graded alcohol series (100-75%) and stained with hematoxylin/eosin. For 
assessment of angiogenesis, tumor, lung, and liver vessels were stained with CD31. For CD31 staining, frozen 
sections were fixed in 80% methanol (VWR, Leuven, Belgium) for 10 minutes at -20°C. Endogenous peroxidase 
was subsequently blocked with 3% H2O2/H2O (Sigma-Aldrich, Steinheim, Germany) for 20 minutes, and non-
specific binding was prevented in normal rabbit serum for 1 hour at RT. Sections were then incubated first with a 
rat monoclonal anti-CD31 (1/250; BD Biosciences, Erembodegem, Belgium) for 1 hour at RT, then with a 
biotinylated secondary antibody (1/400; DAKO, Heverlee, Belgium) for 30 minutes at RT. This was followed by 
incubation with streptavidin/horseradish peroxidase complex (1/500; DAKO, Heverlee, Belgium). CD31-
positive cells were visualized after coloring sections for 3 minutes with 3-amino-9-ethylcarbazole (DAKO, 
Heverlee, Belgium). The sections were finally counterstained with hematoxylin and mounted for microscopy 
with Aqua Polymount (Polysciences, Warrington, PA). 
Image processing and measurements 
Images were digitized in 1,360 × 1,024 pixels in the red-green-blue color space. Image processing and 
measurements were performed with the software Aphelion 3.2 from Adsis (France) on a personal computer. 
Fifteen images, counting a total of ~500 vessels, were analyzed for each condition. 
Immunostaining for CD31 of histological tumor sections is used to distinguish tumor vessels from tissue. They 
appear in red in the red-green-blue color image (Figure 4b, A). The red component of the red-green-blue color 
image was first extracted and the resulting image (Figure 4b, B) was further processed as follows: (i) tumor 
vessels were segmented automatically using the entropy of the histogram of gray-level intensities30; (ii) an 
erosion morphological filter was applied to eliminate small artifacts; (iii) as this last operation reduces the size of 
vessels, a geodesic dilation was carried out to make them recover their real sizes; (iv) all vessels touching the 
border of the image were eliminated (Figure 4b, C); (v) in order to identify and measure the area of each vessel, 
the vessels were labeled with different colors (Figure 4b, D). 
The following measurements were performed: 
(i) Vessel density defined as the number of vessels per unit of tissue area.  
(ii) Area density defined as the percentage of tissue area occupied by vessels.  
(iii) Vessel size distribution. 
Statistical analysis 
All data are expressed as means ± SE. Analyses for statistical significance (the Mann-Whitney test) were carried 
out with Prism 4.0 software (GraphPad Software, San Diego, CA). Statistical significance was set at P < 0.05. 
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